作者：
Suder, A. [1]
;
Ang, J. E. [2]
;
Kyle, F. [3]
;
Harris, D. [4]
;
Rudman, S. [5]
;
Kristeleit, R. [6]
;
Solca, F. [7]
;
Uttenreuther-Fischer, M. [8]
;
Pemberton, K. [9]
;
Pelling, K. ;
Schnell, D. ;
de Bono, J. ;
Spicer, J.
作者单位：
Boehringer Ingelheim Ltd, Biometr & Data Management, Bracknell RG12 8YS, Berks, England
[1]
Boehringer Ingelheim GmbH & Co KG, Translat Med & Clin Pharmacol, D-88397 Biberach, Germany
[2]
Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England
[3]
Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England
[4]
Boehringer Ingelheim RCV GmbH & Co KG, Pharmacol & Translat Res, A-1120 Vienna, Austria
[5]
Boehringer Ingelheim RCV GmbH & Co KG, Therapeut Area Oncol, D-88397 Biberach, Germany
[6]
Kings Coll London, Guys Hosp, Div Canc Studies, London SE1 9RT, England
[7]
Boehringer Ingelheim Ltd, Dept Med, Bracknell RG12 8YS, Berks, England
[8]
Guys & St Thomas NHS Fdn, Dept Med Oncol, London SE1 9RT, England
[9]
发布时间
2016-01-14
换一批
![European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)](https://cdnimg.med.wanfangdata.com.cn/imgs/qkindeximg/N2007EPST0000700/N2007EPST0000700.jpg)
